1. Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN trial
- Author
-
Lomax, Anna J., Yee Yap, Saw, White, Karen, Beith, Jane, Abdi, Ehtesham, Broad, Adam, Sewak, Sanjeev, Lee, Chooi, Sambrook, Philip, Pocock, Nicholas, Henry, Margaret J., Yeow, Elaine G., Bell, Richard, Lomax, Anna J., Yee Yap, Saw, White, Karen, Beith, Jane, Abdi, Ehtesham, Broad, Adam, Sewak, Sanjeev, Lee, Chooi, Sambrook, Philip, Pocock, Nicholas, Henry, Margaret J., Yeow, Elaine G., and Bell, Richard
- Abstract
Abstract: Postmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associated bone loss (AIBL) and fractures. In 2005 Osteoporosis Australia proposed an algorithm for bisphosphonate intervention. Three hundred and three postmenopausal women with early breast cancer (EBC) were enrolled (osteoporotic, n=25; osteopaenic, n=146; normal bone mineral density (BMD), n=126). Weekly alendronate (70 mg) treatment efficacy as triggered by the algorithm in preventing bone loss was evaluated. All patients received anastrozole (1 mg daily), calcium and vitamin D. In postmenopausal women with endocrine-responsive EBC, BMD improved over time when a bisphosphonate is administered with anastrozole in osteoporotic patients using an osteoporosis schedule. Subjects with normal baseline BMD experienced the greatest BMD loss, although none became osteoporotic.
- Published
- 2013